Go Ikeda

Dr. Go Ikeda

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
リスリサコ スズキ
リサコ スズキ
RORyotaro Ohkuma
Ryotaro Ohkuma
MWMakoto Watanabe
Makoto Watanabe
EMEmiko Mura
Emiko Mura
TTToshiaki Tsurui
Toshiaki Tsurui
Satoshi WADASatoshi WADA
Satoshi WADA
Background/Objectives: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; however, their efficacy varies among patients. Eosinophils have been reported as prognostic markers in chemotherapy-treated pancreatic cancer; however, these studies are limited mainly to single cancer types and relatively small cohorts. Therefore, we aimed to examine the relationship between eosinophil count and the effectiveness of ICIs across various cancer types. Methods: We retrospectively analyzed 138 patients treated with ICI monotherapy, ICI plus chemotherapy, or chemotherapy alone at our institution between December 2015 and September 2024. Peripheral blood parameters, including eosinophil counts and albumin levels, were collected at baseline and after two cycles of treatment. Associations between overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan–Meier analysis and Cox proportional hazards regression. Results: In the ICI monotherapy group, patients with higher baseline eosinophil counts had significantly longer OS (HR 0.26, p = 0.007) and PFS (HR 0.30, p = 0.005). No significant associations were observed between the ICI plus chemotherapy and chemotherapy-alone groups. Changes in eosinophil counts between baseline and after two cycles were not associated with outcomes in any group. Conclusions: Baseline eosinophil counts were significantly associated with survival outcomes in patients receiving ICI monotherapy and may serve as a promising predictive biomarker.

21 December 2023 in Future Oncology
Verified
Journal Article
Open access
GIGo Ikeda
Go Ikeda
JMJun Miyakoshi
Jun Miyakoshi
SYShun Yamamoto
Shun Yamamoto
KKKen Kato
Ken Kato
Esophageal cancer (EC) is the eighth most common cancer worldwide. In view of biology and anatomical restrictions, multimodality treatment strategies have been developed for EC. However, the progno... Tweetable abstract Advanced esophageal cancer has a poor prognosis that has improved with nivolumab-containing therapy. This review provides an overview of nivolumab-containing therapy for various ...

18 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MWMakoto Watanabe
Makoto Watanabe
KIKatsuaki Ieguchi
Katsuaki Ieguchi
TSTakashi Shimizu
Takashi Shimizu
RORyotaro Ohkuma
Ryotaro Ohkuma
リスリサコ スズキ
リサコ スズキ
Satoshi WADASatoshi WADA
Satoshi WADA
Background/Objectives: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy; however, reliable biomarkers of therapeutic efficacy remain limited. We investigated the clinical utility of plasma WFDC2 levels in patients receiving anti-PD-1 antibody treatment. Methods: Twenty-one patients with non-small cell lung, gastric, or bladder cancer received nivolumab or pembrolizumab. Plasma WFDC2 concentrations were measured by ELISA before ICI treatment (pre-ICI) and after two and four treatment cycles. Associations between WFDC2 expression changes and overall survival (OS), progression-free survival (PFS), and tumor progression were assessed. ROC curve analyses compared the predictive performance of WFDC2, soluble PD-L1 (sPD-L1), soluble PD-1 (sPD-1), and their combinations, with the area under the curve (AUC) evaluating predictive accuracy. Results: Levels of WFDC2 pre-ICI and those after two cycles were significantly higher than levels in healthy donors. However, no significant differences in WFDC2 levels were found between the time points during treatment. Greater increases in WFDC2 levels were significantly correlated with shorter OS (p = 0.002), shorter PFS (p = 0.037), and tumor progression (p = 0.003). ROC analysis revealed that WFDC2 achieved a higher AUC (0.700) than sPD-L1 (0.538) or sPD-1 (0.650). Combining biomarkers improved the predictive accuracy, with sPD-L1 plus WFDC2 showing the highest AUC (0.825). Conclusions: Serial increases in plasma WFDC2 are associated with poor clinical outcomes, highlighting its potential as a biomarker. Baseline plasma WFDC2 outperformed sPD-L1 and sPD-1 diagnostically. These findings should be interpreted as exploratory and hypothesis-generating, requiring confirmation in larger, tumor-specific cohorts with multivariate adjustment. WFDC2 represents a promising minimally invasive biomarker for the early identification of patients unlikely to benefit from ICI therapy.

31 March 2026 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
GIGo Ikeda
Go Ikeda
Susumu HijiokaSusumu Hijioka
Susumu Hijioka
YTYuka Takahashi
Yuka Takahashi
YNYoshikuni Nagashio
Yoshikuni Nagashio
SHShota Harai
Shota Harai
NHNobuyoshi Hiraoka
Nobuyoshi Hiraoka

29 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
RORyotaro Ohkuma
Ryotaro Ohkuma
TITomoyuki Ishiguro
Tomoyuki Ishiguro
HAHirotsugu Ariizumi
Hirotsugu Ariizumi
MSMasahiro Shimokawa
Masahiro Shimokawa
GIGo Ikeda
Go Ikeda
HAHoriike Atsushi
Horiike Atsushi
Background/Objectives: Evidence regarding associations between local therapy before an indexed systemic regimen and subsequent outcomes in advanced soft tissue sarcoma (STS) remains limited. We evaluated outcomes within four regimen-defined cohorts and explored associations with prior local-therapy history. Methods: This retrospective cohort included 75 patients with recurrent or metastatic STS who contributed 155 treatment episodes: doxorubicin (n = 44), trabectedin (n = 31), pazopanib (n = 42), and eribulin (n = 38). Progression-free survival (PFS) and overall survival (OS) were measured from initiation of the indexed regimen. Surgery, local ablative therapy, and radiation therapy were assessed separately and in combined categories. Post hoc analyses were restricted to leiomyosarcoma. Results: Median PFS was 3.4, 3.1, 5.1, and 3.9 months, respectively. PFS was longer with any local therapy and surgery and/or ablation in the trabectedin cohort (p = 0.0342 and p = 0.0111) and with surgery and/or ablation in the eribulin cohort (p = 0.0352). Longer indexed-regimen OS was observed in surgery-containing categories in the doxorubicin and eribulin cohorts. In selected multivariable models, local therapy was associated with OS in doxorubicin- and eribulin-treated episodes and with PFS in eribulin-treated episodes. Leiomyosarcoma-restricted analyses did not consistently reproduce the full-cohort findings. Conclusions: Prior local-therapy history was associated with PFS or OS in selected within-cohort analyses. The associations may reflect local-treatment effects, differences among selected patients, or both; however, the study cannot distinguish these contributions. No between-regimen differences were formally tested. These findings support individualized multidisciplinary assessment and external validation.

24 January 2024 in Research Square
Verified
Preprint
Open access
PDF file
GIGo Ikeda
Go Ikeda
SYShun Yamamoto
Shun Yamamoto
IAIkuko Azuma
Ikuko Azuma
TKToru Kadono
Toru Kadono
AOAkihiro Ohara
Akihiro Ohara
KKKen Kato
Ken Kato
Background Preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) has become the standard treatment for resectable esophageal squamous cell carcinoma (ESCC) based on the results of the JCOG1109 trial. However, preoperative DCF is associated with a high frequency of febrile neutropenia (FN), especially in elderly patients with risk factors for FN. The utility of primary prophylactic pegfilgrastim (PPP) on day 3 of preoperative DCF for preventing FN was demonstrated in a Phase II study, but it did report comparison data in elderly ESCC patients. We aimed to evaluate the utility of PPP in these patients. Methods We retrospectively evaluated the clinical utility of PPP on day 3 of preoperative DCF in elderly patients with resectable ESCC. The patients were divided into a day 3 pegfilgrastim group (D3PG) and a no pegfilgrastim group (NPG). The incidence of FN and grade ≥ 3 neutropenia, histopathological effects, and relapse-free survival (RFS) were compared between the groups. Results Thirty patients were enrolled in each group. FN was observed in 3.3% of patients in the D3PG and 26.6% of those in the NPG (p = 0.026), and grade ≥ 3 neutropenia was observed in 10% and 70%, respectively (p < 0.001). The pathological complete response rate was 24.1% in the D3PG and 33.3% in the NPG (p = 0.436); the respective 3-year RFS rates were 70.1% and 57.1% (p = 0.304). Conclusion PPP on day 3 of preoperative DCF significantly reduced the risks of FN and grade ≥ 3 neutropenia in elderly patients with ESCC. There was no significant difference between the groups in histological effects or RFS.